National Institute of Allergy and Infectious Diseases, Notice of Closed Meeting, 9580-9581 [08-773]
Download as PDF
pwalker on PROD1PC71 with NOTICES
9580
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
trachoma, making it the most prevalent
form of infectious preventable
blindness. Urogenital infections are the
leading cause of bacterial sexually
transmitted disease in both
industrialized and developing nations.
Moreover, sexually transmitted diseases
are risk factors for infertility, the
transmission of HIV, and human
papilloma virus-induced cervical
neoplasia. Control of C. trachomatis
infections is an important public health
goal. Unexpectedly, however, aggressive
infection control measures based on
early detection and antibiotic treatment
have resulted in an increase in infection
rates, most likely by interfering with
natural immunity, a concept suggested
by studies performed in experimental
infection models. Effective management
of chlamydial disease will likely require
the development of an efficacious
vaccine.
This technology claims vaccine
compositions that comprise an
immunologically effective amount of
PmpD protein from C. trachomatis. Also
claimed in the application are methods
of immunizing individuals against C.
trachomatis. PmpD is an antigenically
stable pan-neutralizing target that, in
theory, would provide protection
against all human strains, thus allowing
the development of a univalent vaccine
that is efficacious against both blinding
trachoma and sexually transmitted
disease.
Application: Prophylactics against C.
trachomatis.
Developmental Status: Preclinical
studies have been performed.
Inventors: Harlan Caldwell and
Deborah Crane (NIAID).
Publication: DD Crane et al.
Chlamydia trachomatis polymorphic
membrane protein D is a speciescommon pan-neutralizing antigen. Proc
Natl Acad Sci USA. 2006 Feb
7;103(6):1894–1899.
Patent Status: PCT Patent Application
No. PCT/US2007/001213 filed 16 Jan
2007, which published as WO 2007/
082105 on 19 Jul 2007 (HHS Reference
No. E–031–2006/0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Collaborative Research Opportunity:
The NIAID Laboratory of Intracellular
Parasites is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize PmpD vaccine
development. Please contact Harlan D.
Caldwell, at hcaldwell@niaid.nih.gov or
406–363–9333 for more information.
VerDate Aug<31>2005
16:34 Feb 20, 2008
Jkt 214001
Dated: February 11, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–3164 Filed 2–20–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel.
Date: March 19, 2008.
Time: 2 pm to 5 pm.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Rebecca Wagenaar Miller,
PhD., Scientific Review Officer, Scientific
Review Branch, National Inst of Dental &
Craniofacial Research, National Institutes of
Health, 6701 Democracy, Rm 666, Bethesda,
MD 20892, 301–594–0652,
rwagenaa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: February 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–771 Filed 2–20–08; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00065
Fmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Dental and Craniofacial Research Special
Emphasis Panel; Review RFA DE08–008,
Centers for Research to Reduce Disparities in
Oral Health.
Date: March 5–6, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza, 10 Thomas
Circle, NW., Washington, DC 20005.
Contact Person: Mario Rinaudo, MD,
Scientific Review Officer, Scientific Review
Branch, National Inst of Dental & Craniofacial
Research, National Institutes of Health, 6701
Democracy Blvd (DEM 1), RM 670 MSC4878,
Bethesda, MD 20892, 301–594–2904)
mrinaudo@nidcr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
February 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–772 Filed 2–20–08: 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases, Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
Sfmt 4703
E:\FR\FM\21FEN1.SGM
21FEN1
Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Regulation of Adaptive
Immunity by the Innate Immune System.
Date: March 13, 2008.
Time: 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, MSC 3136, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Mercy R. Prabhudas, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, 301–
451–2615, mp457n@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–773 Filed 2–20–08; 8:45 am]
National Institutes of Health
pwalker on PROD1PC71 with NOTICES
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
Jkt 214001
Dated: February 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 08–774 Filed 2–20–08: 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
License: Development and
Commercialization of Therapeutic
Products for Breast Cancer
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
16:34 Feb 20, 2008
Name of Committee: National Institute on
Aging Special Emphasis Panel; SWAN.
Date: March 4, 2008.
Time: 2 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20814 (Telephone Conference Call).
Contact Person: Alicja L. Markowska, PhD,
DSC, National Institute on Aging, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–496–9666,
markowsa@nia.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
AGENCY:
BILLING CODE: 4140–01–M
VerDate Aug<31>2005
would constitute a clearly unwarranted
invasion of personal privacy.
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), announces that the
Department of Health and Human
Services is contemplating the grant of an
exclusive license to practice the
inventions embodied in U.S. Patent
Application No. 09/693,600 filed
October 20, 2000 entitled ‘‘Method and
Composition for Enhancing Immune
Response’’ [E–037–2001/1–US–01];
Japanese Patent Application No. 2002–
555834 filed October 22, 2001 entitled
‘‘Method and Composition for
Enhancing Immune Response’’ [E–037–
2001/1–JP–03]; and European Patent
Application No. 01989341.1 filed
October 22, 2001 entitled ‘‘Method and
Composition for Enhancing Immune
Response’’ [E–037–2001/1–EP–04]; to
ODC Therapy, Inc.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to
therapeutic applications for breast
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
9581
cancer patients expressing high levels of
serum or plasma IgE.
DATES: Only written comments and/or
license applications which are received
by the National Institutes of Health on
or before April 21, 2008 will be
considered.
ADDRESSES: Requests for copies of the
patent and/or patent applications,
inquiries, comments and other materials
relating to the contemplated exclusive
license should be directed to: Mojdeh
Bahar, J.D., M.A., Technology Licensing
Specialist, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD. 20852–3804. Telephone:
(301) 435–2950; Facsimile: (301) 402–
0220; E-mail: baharm@od.nih.gov.
SUPPLEMENTARY INFORMATION: The
invention relates to a method of
inhibiting tumor growth which
comprises the administration of an IL–
13 inhibitor. Additionally, the invention
relates to a method and composition for
enhancing an immune response in a
subject by administering to a subject an
inhibitor of IL–13 or an inhibitor of an
NK–T cell. The method can be used to
prevent growth of a tumor in a subject,
e.g., to inhibit tumor recurrence or
metastasis. The method can also be used
to enhance a response to a vaccine in a
subject. IL–13 is an interleukin which
has potent immunomodulatory effects.
It is primarily secreted by TH2
lymphocytes. This invention relates to
the discovery of a role for IL–13 in the
down-regulation of tumor
immunosurveillance. Using a mouse
model in which tumors show a growthregression-recurrence pattern, the
mechanisms for down-regulation of
cytotoxic T lymphocyte-mediated tumor
immunosurveillance was investigated. It
was discovered that interleukin 4
receptor (IL–4R) knockout mice, and
downstream signal transducer and
activator of transcription 6 (STAT6)
knockout mice, but not IL–4 knockout
mice, resisted tumor recurrence. Thus,
IL–13, the only other cytokine that uses
the IL–4R–STAT6 pathway, was
discovered to have a role in the downregulation of tumor
immunosurveillance.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establish that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
E:\FR\FM\21FEN1.SGM
21FEN1
Agencies
[Federal Register Volume 73, Number 35 (Thursday, February 21, 2008)]
[Notices]
[Pages 9580-9581]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 08-773]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases, Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 9581]]
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Regulation of Adaptive Immunity by
the Innate Immune System.
Date: March 13, 2008.
Time: 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6700B Rockledge Drive, MSC
3136, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Mercy R. Prabhudas, PhD, Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, NIAID/NIH/DHHS, 6700B Rockledge Drive, MSC 7616,
Bethesda, MD 20892-7616, 301-451-2615, mp457n@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: February 13, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 08-773 Filed 2-20-08; 8:45 am]
BILLING CODE: 4140-01-M